Although treatment with either aPD-1 mAb or siVegfr2 enhanced tumor infiltrating CD8+ T cells in tumors by two to three-fold compared with control treatment, the combination further increased the infiltration of CD8+ T cells into tumors by 5.5-fold. Here, CD8A is linked to neoplasm.